Evidence map›Paper›PMID 36289430›Full record

ArticleScientific reports2022

In vitro and ex vivo anti-myeloma effects of nanocomposite As

Danka Cholujova, Lenka Koklesova, Zdenka Lukacova Bujnakova, Erika Dutkova, Zuzana Valuskova, Patricia Beblava, Anna Matisova, Jan Sedlak, Jana Jakubikova

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Nanomedicine-Based Strategies for Multiple Myeloma Therapy.International journal of nanomedicine · 2026
    Review
  2. Review
  3. Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Danka CholujovaDepartment of Tumor Immunology, Biomedical Research Center, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, 84505, Slovakia.
Lenka KoklesovaDepartment of Tumor Immunology, Biomedical Research Center, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, 84505, Slovakia.
Zdenka Lukacova BujnakovaDepartment of Mechanochemistry, Institute of Geotechnics, Slovak Academy of Sciences, Watsonova 45, Košice, 04001, Slovakia.
Erika DutkovaDepartment of Mechanochemistry, Institute of Geotechnics, Slovak Academy of Sciences, Watsonova 45, Košice, 04001, Slovakia.
Zuzana ValuskovaDepartment of Tumor Immunology, Biomedical Research Center, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, 84505, Slovakia.
Patricia BeblavaDepartment of Tumor Immunology, Biomedical Research Center, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, 84505, Slovakia.
Anna MatisovaDepartment of Tumor Immunology, Biomedical Research Center, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, 84505, Slovakia.
Jan SedlakDepartment of Tumor Immunology, Biomedical Research Center, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, 84505, Slovakia.
Jana JakubikovaDepartment of Tumor Immunology, Biomedical Research Center, Cancer Research Institute, Slovak Academy of Sciences, Dubravska Cesta 9, Bratislava, 84505, Slovakia. jana.jakubikova@savba.sk.
Cancer Research Institute of the Slovak Academy of Sciences · SKSlovak Academy of Sciences · SKCentre for Advanced Material Application of the Slovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanoparticles in medicine can integrate actively targeted imaging agents and drug delivery vehicles, and combining multiple types of therapeutics in a single particle has numerous advantages, especially in multiple myeloma. MM is an incurable hematological disorder characterized by clonal proliferation of plasma cells in the bone marrow. In this study, we evaluated the anti-myeloma activity of 3 nanocomposites (3NPs): As

Indexed as

Multiple MyelomaNanocompositesAlbuminsApoptosisArsenicalsCaspasesCell Line, TumorCyclin B1Ferric CompoundsFolic AcidHistonesHumansLenalidomideMelphalanSulfidesTOR Serine-Threonine KinasesAlbuminsArsenicalsCaspasesCyclin B1Ferric Compoundsferric oxideFolic AcidHistonesLenalidomideMelphalanSulfidestetraarsenic tetrasulfideTOR Serine-Threonine KinasesZinc Compoundszinc sulfide

Identifiers

PMID36289430
PMCPMC9606304
OpenAlexW4307566873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.